MBX Biosciences Stock Forecast
NASDAQ: MBXHealth CareBiotechnology: Pharmaceutical PreparationsUSD
Market open · Delayed 15 min · as of Oct 8, 9:55 AM ET
MBX analyst consensus
Consensus (11 analysts)
strong_buy
Avg. price target
$94.30+75.95%
- Strong buy 3
- Buy 8
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
What analysts say
According to 11 Wall Street analysts covering MBX Biosciences (2026-10-08), 11 rate the stock a buy or strong buy, 0 rate it a hold and 0 rate it a sell or strong sell, for a consensus rating of "strong_buy". The average 12-month price target is $94.30, with a high estimate of $150.00 and a low estimate of $70.00. The average target implies upside of 76.0% from the current price of $53.59.
The spread between the highest and lowest targets is 114.3%, a wide range that reflects significant disagreement among analysts. Price targets and ratings are the opinions of third-party analysts, not MetaCap. They are frequently revised and have a mixed track record, so treat them as one input among many for MBX.
Summary generated from market data by MetaCap's automated system. Methodology
Rating distribution
| Rating | Analysts | Share |
|---|---|---|
| Strong buy | 3 | 27% |
| Buy | 8 | 73% |
| Hold | 0 | 0% |
| Sell | 0 | 0% |
| Strong sell | 0 | 0% |
Ratings as of 2026-10-08.
Price target scenarios
| Target | Price | vs. current |
|---|---|---|
| Low target | $70.00 | +30.61% |
| Average target | $94.30 | +75.95% |
| High target | $150.00 | +179.88% |